After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Marinus Pharmaceuticals Inc is $29.69M. A total of 3.97 million shares were traded on the day, compared to an average of 3.23M shares.
In the most recent transaction, Saraswathy Nochur bought 13,250 shares of MRNS for 0.28 per share on Dec 10 ’24. In a previous transaction on Aug 05 ’24, Pfanstiel Steven sold 4,657 shares at 1.13 per share. MRNS shares that CFO AND COO owns now total 79,773.
Among the insiders who sold shares, Shafer Christina disposed of 3,820 shares on Aug 05 ’24 at a per-share price of $1.14. This resulted in the CHIEF COMMERCIAL OFFICER holding 67,406 shares of MRNS after the transaction. In another insider transaction, MANNING MARTHA E sold 3,621 shares at $1.13 per share on Aug 05 ’24. Company shares held by the SVP, GEN. COUNSEL & CORP. SEC. now total 60,263.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, MRNS has a high of $11.26 and a low of $0.22.
As of this writing, MRNS has an earnings estimate of -$0.35 per share for the current quarter. EPS was calculated based on a consensus of 3.0 estimates, with a high estimate of -$0.33 per share and a lower estimate of -$0.38.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. MRNS’s latest balance sheet shows that the firm has $122.93M in Cash & Short Term Investments as of fiscal 2021. There were $43.34M in debt and $40.57M in liabilities at the time. Its Book Value Per Share was -$1.21, while its Total Shareholder’s Equity was $53.49M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MRNS is Buy with a score of 3.44.
